SV Health Investors’s Astria Therapeutics ATXS Stock Holding History

SV Health Investors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-47,628	Closed	-$1.77M	–	10
2020 Q3	$1.77M	Hold	47,628	–	–	0.9%	9
2020 Q2	$1.84M	Hold	47,628	–	–	1.27%	9
2020 Q1	$1.19M	Hold	47,628	–	–	0.99%	9
2019 Q4	$1.69M	Hold	47,628	–	–	1.02%	9
2019 Q3	$1.54M	Hold	47,628	–	–	1.08%	10
2019 Q2	$2.31M	Hold	47,628	–	–	1.55%	9
2019 Q1	$2.26M	Hold	47,628	–	–	1.33%	8
2018 Q4	$1.25M	Hold	47,628	–	–	0.77%	8
2018 Q3	$2.29M	Hold	47,628	–	–	0.67%	8
2018 Q2	$2.74M	Hold	47,628	–	–	1.26%	7
2018 Q1	$5.17M	Hold	47,628	–	–	3.88%	6
2017 Q4	$4.26M	Hold	47,628	–	–	2.25%	7
2017 Q3	$6.06M	Hold	47,628	–	–	4.59%	6
2017 Q2	$4.03M	Hold	47,628	–	–	4.34%	5
2017 Q1	$4.57M	Hold	47,628	–	–	5.05%	5
2016 Q4	$10.3M	Hold	47,628	–	–	8.69%	4
2016 Q3	$17.6M	Hold	47,628	–	–	13.52%	2
2016 Q2	$10.6M	Hold	47,628	–	–	10.68%	2
2016 Q1	$14.4M	Hold	47,628	–	–	10.76%	4
2015 Q4	$22.7M	Hold	47,628	–	–	18.22%	2
2015 Q3	$23.1M	Hold	47,628	–	–	12.93%	4
2015 Q2	$34.9M	Buy	+47,628	New	+$36M	13.36%	4

Other funds holding ATXS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

SV Health Investors's ATXS Position: Q4 2020 in Review

SV Health Investors sold out of Astria Therapeutics (ATXS) in Q4 2020, closing a stake of 47,628 shares — an estimated $1.77M sold.

SV Health Investors first reported a position in ATXS in Q2 2015 and held it in 22 quarters. The position peaked at $34.9M in Q2 2015. 62 funds tracked by Wall St. Rank hold ATXS as of Q4 2020.

SV Health Investors reported no remaining Astria Therapeutics position as of Q4 2020 after selling out during the quarter.
SV Health Investors sold 47,628 Astria Therapeutics shares in Q4 2020, an estimated $1.77M.
SV Health Investors first reported a position in Astria Therapeutics in Q2 2015 and held it in 22 quarters.
SV Health Investors's Astria Therapeutics position peaked at $34.9M in Q2 2015.
62 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2020.

Based on SV Health Investors's 13F filing for Q4 2020, filed 16 Feb 2021.